Yüksel Ürün: Adding immunotherapy to cabozantinib for mccRCC after 1st line immunotherapy showed no extra benefit in real-world data

Yüksel Ürün, Doctorate Professor at the Faculty of Medicine, Ankara University, Turkey, shared a post by ACS Journal Cancer, on X:

“Adding immunotherapy to cabozantinib for metastatic clear cell renal cell carcinoma after 1st line immunotherapy showed no extra benefit in real-world data. This strengthens evidence against re-challenging with immunotherapy after it stopped working. Congrats Georges Gebrael, Neeraj Agarwal, Umang Swami et al.”

Quoting ACS Journal Cancer‘s post:

“Results align with the phase 3 CONTACT-03 trial results, which showed no additional benefit of adding PD-L1 inhibitor to cabozantinib vs cabozantinib alone in 2L following PD-1/L1–based therapies in 1L.”

Read further.
Source: Yüksel Ürün/X and ACS Journal Cancer/X